Adefovir Dipivoxil interactions
Full monograph for Adefovir DipivoxilCheck it against another medicine
Medicines
155 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amikacin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Amphotericin B | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Bromfenac Sodium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Cisplatin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Colistimethate Sodium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Deferasirox | Major | Synergy | Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents. | 2 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Diclofenac Potassium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Diclofenac Sodium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Major | Excretion · Unknown | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Etodolac | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Fluocinolone Acetonide + Neomycin Sulfate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Fluormetholone + Neomycin Sulphate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Fluorometholone + Gentamicin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Flurbiprofen | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Gentamicin + Hydrocortisone Acetate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Gentamicin SulfateInjectionOphthalmic | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Gramacidin + Neomycin + Polymixin B | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Human Anti-D Immunoglobulins | Major | Synergy | Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. | 11 sources — open the full entry |
| Hydrocortisone + Neomycin Sulphate + Polymixin B | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Hydrocortisone Acetate + Neomycin Sulphate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Iodixanol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iohexol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iopamidol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Ketorolac Tromethamine | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Lithium Carbonate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Loteprednol Etabonate + Tobramycin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Mefenamic acid | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Meloxicam | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Mesalazine [5-aminosalicylic acid] | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Methotrexate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Metronidazole + Neomycin Sulphate + Polymyxin B + Nystatin | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Nabumetone | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Naproxen Sodium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Naproxen Sodium + Esomeprazole Magnesium | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zinc | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zinc + Polymyxin B Sulfate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…3 documented mechanisms | 1 sources — open the full entry |
| Neomycin Sulphate + Polymyxin B Sulphate + Pramoxine | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 1 sources — open the full entry |
| Oxytetracycline + Polymixin B Sulphate | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
Conditions
Conditions in which Adefovir Dipivoxil needs care, as documented in this source.
Kidney Diseases
MajorAdefovir is primarily eliminated by the kidney via glomerular filtration and active tubular secretion. Renal impairment, including acute renal failure and Fanconi syndrome, has been reported with adefovir use. Close monitoring of renal function and lengthening the dosing interval are recommended for patients with creatinine clearance less than 50 mL/min. Creatinine clearance should be calculated in all patients before starting adefovir treatment and during treatment when clinically appropriate. Routine monitoring of serum creatinine and phosphorus is recommended for patients at risk of or with a history of renal dysfunction. Safety and effectiveness have not been evaluated in patients with renal insufficiency using dose adjustments; therefore, the benefit of adefovir treatment should be weighed against the risk of renal toxicity. Adefovir should be avoided in patients who are currently using or have recently used nephrotoxic drugs.
1 source
- "Product Information. Hepsera (adefovir)." Gilead Sciences (2022):
Kidney Diseases
MajorAdefovir is primarily eliminated by the kidney via glomerular filtration and active tubular secretion. Renal impairment, including acute renal failure and Fanconi syndrome, has been reported with adefovir use. Close monitoring of renal function and lengthening the dosing interval are recommended for patients with creatinine clearance less than 50 mL/min. Creatinine clearance should be calculated in all patients before starting adefovir treatment and during treatment when clinically appropriate. Routine monitoring of serum creatinine and phosphorus is recommended for patients at risk of or with a history of renal dysfunction. Safety and effectiveness have not been evaluated in patients with renal insufficiency using dose adjustments; therefore, the benefit of adefovir treatment should be weighed against the risk of renal toxicity. Adefovir should be avoided in patients who are currently using or have recently used nephrotoxic drugs.
1 source
- "Product Information. Hepsera (adefovir)." Gilead Sciences (2022):